Seeking Alpha

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) RICHMOND, Va.
Seeking Alpha

Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two approaches ...
WGNO

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data ...

Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...
WDIO

St. Louis County Jail offering medication for inmates with addictions

Fighting an addiction is hard, but it can be even more difficult for an addict when they’re in jail or prison. Although for the past few years the St. Louis County Jail has used a Medication Assisted ...
Psychology Today

Sublocade: Directionally Positive But Not a Panacea

The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...